Plain-English translation of NCT06820333 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying whether a newer imaging scan called [18F] PSMA-1007 can better help doctors detect prostate cancer and guide treatment decisions. Previous studies suggest this scan is more effective at finding cancer in lymph nodes compared to traditional scanning methods. This real-world study aims to confirm these benefits in everyday clinical practice with a larger, more diverse group of patients.
While earlier studies showed this scan works very well in controlled settings, doctors want to understand how well it performs in typical medical practice with different types of patients and over longer periods. This trial fills that gap by tracking real outcomes in routine clinical care.
You likely qualify if…
You likely don't qualify if…
As a participant, you would undergo the [18F] PSMA-1007 imaging scan as part of your standard prostate cancer workup—this is likely already planned by your doctor. Researchers will then follow your care over time, collecting information from your medical records about how the scan results affected your treatment decisions and your health outcomes. The study involves no extra procedures beyond the scan you would already be receiving.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Germany
Enrollment target
~200 participants
Started
January 2025
Primary completion
January 2030
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Emil Novruzov, Medical Doctor
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.